Alimera Sciences, Inc.(ALIM)

Description: Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company's principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye to a placement site that takes advantage of the eye's natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME; and in Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is based in Alpharetta, Georgia.

---

Keywords: Medicine Biopharmaceutical Disease Diabetes Organ Systems Eye Macular Degeneration Ophthalmic Diabetic Retinopathy Fluid Dynamics Retina Blindness Diabetic Macular Edema Macular Edema Age Related Macular Degeneration Veins Pivotal Glucocorticoids Pregnanes Corticosteroids Retinal Vein Occlusion Corticosteroid Diketones Fluocinolone

---

Home Page: alimerasciences.com

ALIM Technical Analysis

6310 Town Square
Alpharetta, GA 30005
United States
Phone: 678 990 5740

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)